Literature DB >> 15996508

Pneumocystis: not just pneumonia.

J Chad Peterson1, Melanie T Cushion.   

Abstract

Once known exclusively as the agents of severe pneumonia in immunocompromised individuals, Pneumocystis spp. are now being associated with asymptomatic carriage in hosts that do not have profound immune debilitation. In the absence of a cultivation system, polymerase chain reaction and histological studies have identified Pneumocystis in neonatal populations, in pregnant women and in other patients that have chronic underlying disease processes. These findings in humans and in experimental animal models indicate the presence of potential reservoirs of infection, and provide insights into the transmission of this fungus. Also, the role of Pneumocystis has been investigated as a possible co-morbidity factor.

Entities:  

Mesh:

Year:  2005        PMID: 15996508     DOI: 10.1016/j.mib.2005.06.010

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  20 in total

1.  Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients.

Authors:  Françoise Botterel; Odile Cabaret; Françoise Foulet; Catherine Cordonnier; Jean-Marc Costa; Stéphane Bretagne
Journal:  J Clin Microbiol       Date:  2011-12-07       Impact factor: 5.948

2.  Pneumocystis carinii infection causes lung lesions historically attributed to rat respiratory virus.

Authors:  Robert S Livingston; Cynthia L Besch-Williford; Matthew H Myles; Craig L Franklin; Marcus J Crim; Lela K Riley
Journal:  Comp Med       Date:  2011-02       Impact factor: 0.982

3.  Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii on the fully automated BD MAX platform.

Authors:  Alexander H Dalpke; Marjeta Hofko; Stefan Zimmermann
Journal:  J Clin Microbiol       Date:  2013-05-15       Impact factor: 5.948

4.  Pneumocystis infection in an immunocompetent host can promote collateral sensitization to respiratory antigens.

Authors:  Steve D Swain; Nicole Meissner; Soo Han; Allen Harmsen
Journal:  Infect Immun       Date:  2011-02-22       Impact factor: 3.441

Review 5.  Opportunistic yeast pathogens: reservoirs, virulence mechanisms, and therapeutic strategies.

Authors:  Elizabeth J Polvi; Xinliu Li; Teresa R O'Meara; Michelle D Leach; Leah E Cowen
Journal:  Cell Mol Life Sci       Date:  2015-02-21       Impact factor: 9.261

6.  Pneumocystis jirovecii and Cystic Fibrosis in Brittany, France.

Authors:  Gilles Nevez; Florence Robert-Gangneux; Laurence Pougnet; Michèle Virmaux; Chantal Belleguic; Eric Deneuville; Gilles Rault; Sylviane Chevrier; Sophie Ramel; Jean Le Bihan; Thibaud Guillaud-Saumur; Enrique Calderon; Yohann Le Govic; Jean-Pierre Gangneux; Solène Le Gal
Journal:  Mycopathologia       Date:  2017-07-07       Impact factor: 2.574

7.  Serum (1->3)-beta-D-glucan levels in primary infection and pulmonary colonization with Pneumocystis jirovecii.

Authors:  Céline Damiani; Solène Le Gal; Delphine Lejeune; Naima Brahimi; Michèle Virmaux; Gilles Nevez; Anne Totet
Journal:  J Clin Microbiol       Date:  2011-03-23       Impact factor: 5.948

8.  Primary pneumocystis infection in infants hospitalized with acute respiratory tract infection.

Authors:  Hans Henrik Larsen; Marie-Louise von Linstow; Bettina Lundgren; Birthe Høgh; Henrik Westh; Jens D Lundgren
Journal:  Emerg Infect Dis       Date:  2007-01       Impact factor: 6.883

9.  Imidazoquines as antimalarial and antipneumocystis agents.

Authors:  Nuno Vale; Miguel Prudêncio; Catarina A Marques; Margaret S Collins; Jiri Gut; Fátima Nogueira; Joana Matos; Philip J Rosenthal; Melanie T Cushion; Virgílio E do Rosário; Maria M Mota; Rui Moreira; Paula Gomes
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

10.  Pneumocystis infection enhances antibody-mediated resistance to a subsequent influenza infection.

Authors:  James A Wiley; Allen G Harmsen
Journal:  J Immunol       Date:  2008-04-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.